RT Journal Article
T1 Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI.
A1 Klimek, Ludger
A1 Bergmann, Karl-Christian
A1 Brehler, Randolf
A1 Pfützner, Wolfgang
A1 Zuberbier, Torsten
A1 Hartmann, Karin
A1 Jakob, Thilo
A1 Novak, Natalija
A1 Ring, Johannes
A1 Merk, Hans
A1 Hamelmann, Eckard
A1 Ankermann, Tobias
A1 Schmidt, Sebastian
A1 Untersmayr, Eva
A1 Hötzenecker, Wolfram
A1 Jensen-Jarolim, Erika
A1 Brockow, Knut
A1 Mahler, Vera
A1 Worm, Margitta
K1 Allergic reaction
K1 Anaphylactic reaction
K1 Corona virus
K1 Safety
K1 Vaccination
AB For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral sequence, these vaccines were approved for use in the European Union (EU) as well as in numerous other countries and mass vaccination efforts began. The so far in the EU approved mRNA vaccines BNT162b2 and mRNA-1273 are based on similar lipid-based nanoparticle carrier technologies; however, the lipid components differ. Severe allergic reactions and anaphylaxis after COVID-19 vaccination are very rare adverse events but have drawn attention due to potentially lethal outcomes and have triggered a high degree of uncertainty. Current knowledge on anaphylactic reactions to vaccines and specifically the new mRNA COVID-19 vaccines was compiled using a literature search in Medline, PubMed, as well as the national and international study and guideline registries, the Cochrane Library, and the Internet, with special reference to official websites of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), Robert Koch Institute (RKI), and Paul Ehrlich Institute (PEI). Based on the international literature and previous experience, recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts. Allergy testing is not necessary for the vast majority of allergic patients prior to COVID-19 vaccination with currently licensed vaccines. In case of allergic/anaphylactic reactions after vaccination, allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Evaluation and approval of diagnostic tests should be done for this purpose.
SN 2197-0378
YR 2021
FD 2021-04-19
LK http://hdl.handle.net/10668/17634
UL http://hdl.handle.net/10668/17634
LA en
DS RISalud
RD Apr 12, 2025